Forxiga generics, Jardiance·Envlo, surpass original drug
By Kim, Jin-Gu | translator Kang, Shin-Kook
24.07.18 05:55:51
가나다라
0
'Set to withdraw from KOR' Forxiga's Q2 prescription sales totaled KRW 10.4 billion…sales of 65 generics totaled KRW 10.6 billion
Envlo, a new drug in KOR, had a sixfold increase in sales over a year …Jardiance is the top-selling drug in the market for SGLT2i monotherapy
Generic versions of metformin combination therapy dominate in the market…sales of Jardiance Duo 'stalled'·Xigduo 'decreased'
▲(Clockwise from upper left) Product photos of AstraZeneca
The market for SGLT-2 inhibitors used to treat diabetes is shifting due to advancing generics and new drugs made in South Korea. The prescription sales of Forxiga (dapagliflozin), which is set to withdraw from South Korea, have significantly dropped. In contrast, the prescription sales of Forxiga generics quickly increased, surpassing those of the original drug in one year since its launch.
Similarly, the prescription sales of the new drug in South Korea, 'Envlo (enavogliflozin),' have expanded over sixfold over a year. Analysis suggests that when Forxiga withdraws from the market in the second half of the year, Envlo will likely take second place in the market.
'Set
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)